International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin
Male
Hemorrhage
Middle Aged
Brain Ischemia
3. Good health
Stroke
03 medical and health sciences
Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences
Treatment Outcome
0302 clinical medicine
Predictive Value of Tests
Case-Control Studies
Atrial Fibrillation
Humans
Female
International Normalized Ratio
Warfarin
Cardiology - Radboud University Medical Center
Aged
DOI:
10.1007/s11239-019-01858-1
Publication Date:
2019-04-10T19:14:41Z
AUTHORS (14)
ABSTRACT
We explored associations between INR measures and clinical outcomes in patients with AF using warfarin, and whether INR history predicted future INR measurements. We included patients in ARISTOTLE who were randomized to and received warfarin. Among patients who had events, we included those with ≥ 3 INR values in the 180 days prior to the event, with the most recent ≤ 60 days prior to the event, who were on warfarin at the time of event (n = 545). Non-event patients were included in the control group if they had ≥ 180 days of warfarin exposure with ≥ 3 INR measurements (n = 7259). The median (25th, 75th) number of INR values per patient was 29 (21, 38) over a median follow-up of 1.8 years. A total of 87% had at least one INR value < 1.5; 49% had at least one value > 4.0. The last INRs before events (median 14 [24, 7] days) were < 3.0 for at least 75% of patients with major bleeding and > 2.0 for half of patients with ischemic stroke. Historic time in therapeutic range (TTR) was weakly associated with future TTR (R2 = 0.212). Historic TTR ≥ 80% had limited predictive ability to discriminate future TTR ≥ 80% (C index 0.61). In patients with AF receiving warfarin, most bleeding events may not have been preventable despite careful INR control. Our findings suggest that INRs collected through routine management are not sufficiently predictive to provide reassurance about future time in therapeutic range or to prevent subsequent outcomes, and might be over-interpreted in clinical practice.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (17)
CITATIONS (10)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....